The extremely low reporting rate of cardiovascular adverse events for loratadine, the possible preferential use of loratadine in patients with pre-existing cardiovascular disorders, and the impressive lack of cardiovascular effects at extremely high concentrations in clinical and preclinical studies demonstrate the very safe cardiovascular profile of loratadine.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1046/j.1365-2222.1999.0290s3197.x | DOI Listing |
Publication Analysis
Top Keywords
cardiovascular profile
8
profile loratadine
8
cardiovascular
5
loratadine
4
loratadine extremely
4
extremely low
4
low reporting
4
reporting rate
4
rate cardiovascular
4
cardiovascular adverse
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!